Method of identifying and treating invasive carcinomas

Details Method of identifying and treating invasive carcinomas Method of identifying and treating invasive carcinomas

2005-03-08

2005-03-08

Housel, James (Department: 1648)

Chemistry: analytical and immunological testing

Cancer

C424S009100, C536S023100, C536S023500, C536S024300

Reexamination Certificate

active

06864093

ABSTRACT:
Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of MDA-MB-231 and MDA-MB-435s cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 50% for either cell line. The prostasin gene promoter region was found to be hypermethylated at specific sites in invasive cancer cells.

REFERENCES:
patent: 5686419 (1997-11-01), Powers et al.
patent: 6043033 (2000-03-01), Bandman et al.
patent: 6048970 (2000-04-01), Lal et al.
patent: 6075136 (2000-06-01), Tang et al.
patent: 6090559 (2000-07-01), Russell et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 6107049 (2000-08-01), Allard et al.
Chen et al., International Journal of Cancer, vol. 97 No. 3, ages 323-29 (Jan. 2002).*
Akazaki K. Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. Journal of the National Cancer Institute. 50(5):1137-44, 1973.
Berteau P. Laribi A. Eschwege P. Lebars I. Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect prostate cells in blood of cancer patients. Clinical and Chemical Laboratory Medicine 37 (SS): S119, 1999.
Bussemakers MJ van Moorselaar RJ. Giroldi LA. Ichikawa T. Isaacs JT. Takeichi M. Debruyne FM. Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Research. 52(10):2916-22, 1992.
Catalona WJ. Partin AW. Slawin KM. Brawer MK. Flanigan RC. Patel A. Richie JP. deKernion JB. Walsh PC. Scardino PT. Lange PH. Subong EN. Parson RE. Gasior GH. Loveland KG. Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trail [see comments]. JAMA. 279(19):1542-7, 1998.
Dong JT. Lamb PW. Rinker-Schaeffer CW. Vukanovic J. Ichikawa T. Isaacs JT. Barrett JC. KA11, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [see comments]. Science. 268(2512):884-6, 1995.
Dong JT. Suzuki H. Pin SS. Bova GS. Schalken JA. Isaacs WB. Barrett JC. Isaacs JT. Down-regulation of the KA11 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Research. 56(19):4387-90, 1996.
Dunn JE. Cancer epidemiology in populations of the United States—with emphasis on Hawaii and California—and Japan. Cancer Research. 35(11 Pt. 2):3240-5, 1975.
Fornaro M. Tallini G. Bofetiado CJ Bosari S. Languino LR. Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. American Journal of Pathology. 149(3):765-73, 1996.
Fornaro M. Manzotti M. Tallini G. Slear AE. Bosari S. Ruoslahti E. Languino LR. Beta1C integrin in epithelial cells correlates with a nonproliferative phenotype: forced expression of beta1C inhibits prostate epithelial cell proliferation. American Journal of Pathology. 153(4):1079-87, 1998.
Fornaro M. Tallini G. Zheng DQ. Flanagan WM. Manzotti M. Languino LR. p27(kip1) acts as a downstream effector of and its coexpressed with the beta1C integrin in prostatic adenocarcinoma. Journal of Clinical Investigation. 103(3):321-9, 1999.
Gao AC. Lou W. Dong JT. Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Research. 57(5):846-9, 1997.
Goyal J, Smith KM, Cowan JM. Wazer DE. Lee SW. Band V. The role for NESI serine protease as a novel tumor suppressor. Cancer Res 58:4782-4786, 1998.
Greene GF. Kitadai Y. Pettaway CA. von Eschenbach AC. Bucana CD. Fidler IJ. Correlation of metastasis-related gene expression with metastatic protential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. American Journal of Pathology. 150(5):1571-82, 1997.
Greenlee RT. Murray T. Bolden S. Wingo PA. Cancer statistics. 1999. Ca: a Cancer Journal for Clinicians 2000: 50:7-33.
Hooper JD. Nicol DL. Dickinson JL. Eyre HJ. Searman AL. Normyle JF. Stuttgen MA. Douglas ML. Loveland KA. Sutherland GR. Antalis TM. Testisin. a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors. Cancer Research. 59(13):3199-205, 1999.
Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. [Review] [92 refs] American Journal of Pathology. 150(5):1511-21, 1997.
Isaacs JT. Bova GS. Prostate Cancer. InThe Genetic Basis of Human Cancer(Ed. Vogelstein B and Kinzler KW), pp653-60, McGraw-Hill Health Professions Division. 1998.
Knuutila S. Aalto Y. Autio K. Bjorkqvist AM. El-Rifai W. Hemmer S. Huhta T. Kettunen E. Kiuru-Kuhlefeit S. Larramendy ML. Lushnikova T. Monni O. Pere H. Tapper J. Tarkkanen M. Varis A. Wasenius VM. Wolf M. Zhu Y. DNA copy number losses in human neoplasms. [Review] [197 refs] American Journal of Pathology. 155(3):683-94, 1999.
Liu DF. Rabbani SA. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3, Prostate. 27(5):269-76, 1995.
Lou W. Krill D. Dhir R. Becich MJ. Dong JT. Frierson HF Jr. Isaacs WB. Isaacs JT. Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Research. 59(10):2329-31, 1999.
Lou J. Lubaroff DM. Hendrix MJ. Suppression of prostate cancer invasive protential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Research. 59(15):3552-6, 1999.
Mirchandani D. Zheng J. Miller GJ. Ghosh AK. Shibata DK. Cote RJ. Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. American Journal of Pathology, 147(1):92-101, 1995.
Nelson PS. Gan L. Ferguson C. Moss P. Gelinas R. Hood L. Wang K. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proceedings of the National Academy of Sciences of the United States of America, 96(6):3114-9, 1999.
Noordzij MA. van Steenbrugge GJ. Verkaik NS. Schroder FH. van der Kwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clinical Cancer Research. 3(5):805-15, 1997.
Qian J. Bostwick DG. Takahashi S. Borell TJ. Herath JF. Lieber MM. Jenkins RB. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Research. 55(22):5408-14, 1995.
Saedi MS. Hill TM. Kuus-Reichel K. Kumar A. Payne J. Mikolajczyk SD. Wolfert RL. Rittenhouse HG. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clinical Chemistry, 44(10):2115-9, 1998.
Sakr WA. Macoska JA. Benson P. Grignon DJ. Wolman SR. Pontes JE. Crissman JD. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Research, 54(12):3273-7, 1994.
Stamey TA. McNeal JE. Yemoto CM. Sigal BM. Johnstone IM. Biological determinants

Affiliated with

Also associated with

Rating

Method of identifying and treating invasive carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of identifying and treating invasive carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of identifying and treating invasive carcinomas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3367523